142 related articles for article (PubMed ID: 19823044)
1. Somatostatin analogs and hepatocellular carcinoma: Not dead yet?
Raftery L; O'Neil BH
Cancer Biol Ther; 2009 Nov; 8(21):2040-1. PubMed ID: 19823044
[No Abstract] [Full Text] [Related]
2. Octreotide in hepatocellular carcinoma.
Shouval D
Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
[No Abstract] [Full Text] [Related]
3. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
[No Abstract] [Full Text] [Related]
4. [Somatostatin analogue (octreotide)].
Sano K; Makuuchi M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
[No Abstract] [Full Text] [Related]
5. Somatostatin and hepatocellular carcinoma.
Kapadia CR
Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
[No Abstract] [Full Text] [Related]
6. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
[TBL] [Abstract][Full Text] [Related]
7. The role of somatostatin analogs in the management of hepatocellular carcinoma.
D'Agostino L; Manguso F; Pivonello R; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
[No Abstract] [Full Text] [Related]
8. Octreotide and hepatocellular carcinoma.
Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
[No Abstract] [Full Text] [Related]
9. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
Allgaier HP; Becker G; Blum HE
Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
[No Abstract] [Full Text] [Related]
10. Octreotide treatment of hepatocellular carcinoma.
Kouroumalis E; Samonakis D; Skordilis P
Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
[No Abstract] [Full Text] [Related]
11. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.
Angeletti S; Corleto VD; Schillaci O; Marignani M; Annibale B; Moretti A; Silecchia G; Scopinaro F; Basso N; Bordi C; Delle Fave G
Gut; 1998 Jun; 42(6):792-4. PubMed ID: 9691916
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.
Reynaert H; Colle I
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569719
[TBL] [Abstract][Full Text] [Related]
13. Positive octreotide scan in a case of hepatocellular carcinoma.
Schommartz B; Brill N; Larisch R; Wettstein M; Häussinger D; Müller-Gärtner HW
J Hepatol; 2002 Oct; 37(4):539. PubMed ID: 12217610
[No Abstract] [Full Text] [Related]
14. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight.
Samonakis DN; Christodoulakis N; Kouroumalis EA
J Clin Gastroenterol; 2006 Jan; 40(1):86-7. PubMed ID: 16340641
[No Abstract] [Full Text] [Related]
15. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA
Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571
[TBL] [Abstract][Full Text] [Related]
16. Complete regression of advanced HCC with long acting octreotide.
Siveke JT; Herberhold C; Folwaczny C
Gut; 2003 Oct; 52(10):1531. PubMed ID: 12970151
[No Abstract] [Full Text] [Related]
17. Octreotide inhibits the growth and development of three types of experimental liver metastasis.
Frizelle FA
Br J Surg; 1995 Nov; 82(11):1577. PubMed ID: 8535822
[No Abstract] [Full Text] [Related]
18. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.
Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Markidou S; Panagiotakos D; Chrysohoou C; Bazinis A; Paraskevas E
Hepatogastroenterology; 2002; 49(47):1245-50. PubMed ID: 12239914
[TBL] [Abstract][Full Text] [Related]
19. [Tamoxifen and hepatocarcinoma].
Mondragón Sánchez R
Rev Gastroenterol Mex; 1998; 63(3):169. PubMed ID: 10068765
[No Abstract] [Full Text] [Related]
20. Complete regression of hepatocellular carcinoma under tamoxifen.
Castéra L; Boige V; Rocher L; Duclos-Vallée JC; Fabre M; Buffet C
Am J Gastroenterol; 2000 Mar; 95(3):827-9. PubMed ID: 10710095
[No Abstract] [Full Text] [Related]
[Next] [New Search]
